

## Bristol Myers Squibb | Board of Directors

### **Giovanni Caforio, M.D.**

Board Chair and Chief Executive Officer,  
Bristol Myers Squibb

### **Theodore R. Samuels**

Lead Independent Director, Bristol Myers Squibb  
Retired President of Capital Guardian Trust  
Company  
(a, b)

### **Peter J. Arduini**

President and Chief Executive Officer,  
GE Healthcare  
(c, d)

### **Deepak L. Bhatt, M.D., M.P.H.**

Director of Mount Sinai Heart and the  
Dr. Valentin Fuster Professor of Cardiovascular  
Medicine at the Icahn School of Medicine  
(d)

### **Julia A. Haller, M.D.**

Ophthalmologist-in-Chief, Wills Eye Hospital  
(b, d)

### **Manuel Hidalgo Medina, M.D., Ph.D.**

Chief, Division of Hematology and Medical  
Oncology, Weill Cornell Medicine and New York-  
Presbyterian /Weill Cornell Medical Center  
(b, d)

### **Paula A. Price**

Former Executive Vice President  
and Chief Financial Officer, Macy's, Inc.  
(a, b)

### **Derica W. Rice**

Former EVP, CVS Health and President,  
Pharmacy Benefits Business  
CVS Caremark.  
Former Executive Vice President and Chief  
Financial Officer, Eli Lilly Company  
(a, c)

### **Gerald L. Storch**

Chief Executive Officer, Storch Advisors.  
Former Chief Executive Officer,  
Hudson's Bay Company  
(b, c)

### **Karen H. Vousden, Ph.D.**

Principal Group Leader,  
The Francis Crick Institute  
Former Chief Scientist, Cancer Research UK  
(c, d)

### **Phyllis R. Yale**

Advisory Partner, Bain & Company  
(a, b)

Members of the Board of Directors and Committee memberships as of March 9, 2023

(a) Audit Committee

(b) Committee on Directors and Corporate Governance

(c) Compensation and Management Development Committee

(d) Science and Technology Committee

## Bristol Myers Squibb | Leadership Team

**Giovanni Caforio, M.D.**

Board Chair and  
Chief Executive Officer

**Chris Boerner, Ph.D.**

Executive Vice President,  
Chief Commercialization Officer

**David V. Elkins**

Executive Vice President,  
Chief Financial Officer

**Pamela Fisher**

Vice President,  
Chief Diversity and Inclusion Officer

**Cari Gallman**

Senior Vice President,  
Chief Compliance and Ethics Officer

**Samit Hirawat, M.D.**

Executive Vice President,  
Chief Medical Officer,  
Global Drug Development

**Sandra Leung**

Executive Vice President,  
General Counsel

**Greg Meyers**

Executive Vice President,  
Chief Digital & Technology Officer

**Elizabeth A. Mily**

Executive Vice President,  
Strategy & Business Development

**Ann M. Powell**

Executive Vice President,  
Chief Human Resources Officer

**Karin Shanahan**

Executive Vice President,  
Global Product Development & Supply

**Wendy Short Bartie**

Senior Vice President,  
Chief of Staff to the CEO

**Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil**

Executive Vice President and President,  
Research

**Estelle Vester-Blokland, M.D.**

Senior Vice President,  
Global Medical Affairs

**Michelle Weese**

Executive Vice President,  
Corporate Affairs

## BRISTOL MYERS SQUIBB Stockholder Information

### Common Stock

Ticker symbol: BMY  
New York Stock Exchange

### Contingent Value Right

Ticker Symbol: CELG-RT  
New York Stock Exchange

### Stockholder Services

All inquiries concerning stockholder accounts and stock transfer matters – including address changes, the elimination of duplicate mailings and the Shareowner Services Plus Plan<sup>SM</sup> – should be directed to the Company's Transfer Agent and Registrar:

EQ Shareowner Services  
1110 Centre Pointe Curve, Suite 101  
Mendota Heights, MN 55120-4100  
www.shareowneronline.com  
855-598-5485 (within the U.S.)  
651-450-4064 (outside the U.S.)

A telecommunications relay service should be used by the hearing impaired when calling the telephone numbers above.

Shareowner Services Plus Plan<sup>SM</sup>  
The Shareowner Services Plus Plan<sup>SM</sup> is designed for long-term investors who wish to build share ownership in the Company's common stock over time. You can participate in the plan if you are a registered holder of the Company's common stock. If you do not own the Company's common stock, you can become a participant by making your initial purchase through the plan. The plan features dividend reinvestment, optional cash purchase, share safekeeping, and share sales and transfers. Bristol-Myers Squibb Company has appointed EQ Shareowner Services as Administrator for the plan. The plan is not sponsored or administered by Bristol-Myers Squibb Company.

### Form 10-K

For a free copy of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, contact:

Corporate Secretary\*  
Bristol-Myers Squibb Company  
430 E. 29th Street, 14FL  
New York, NY 10016

The Form 10-K is also available at investor.bms.com

The most recent certifications by the Company's chief executive officer and chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits to the Company's Form 10-K. The Company has also filed with the New York Stock Exchange the most recent Annual CEO Certification as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual.

### Additional Information

Information on the following subjects is available at www.bms.com:

- Bristol Myers Squibb Foundation
- Clinical Trials
- Compliance and Ethics
- Diversity and Workforce Statistics
- Patient Assistance Programs
- Policy and Advocacy Engagement and Political Contributions
- Sustainability/Environmental Programs

This Annual Report contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and involve inherent risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.

Please see page 30 of the Financial Review for a discussion and description of these risks and uncertainties. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Copies of Bristol Myers Squibb's EEO-1 reports are available to shareholders upon request

\*As we plan to relocate our principal executive offices, effective July 1, 2023, at such time, please contact Corporate Secretary, Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543.

### Product Names and Company Programs

Global products and company program names appearing throughout in italics are referred to herein by their registered and approved U.S. trademarks, unless specifically noted otherwise.

*Abilify* is a trademark of Otsuka Pharmaceutical Co., Ltd.

*Atripla* is a trademark of Gilead Sciences, Inc.

*Byetta* is a trademark of Amylin Pharmaceuticals, LLC

*CABOMETYX* is a trademark of Exelixis, Inc.

*Farxiga* and *Onglyza* are trademarks of AstraZeneca AB

*Gleevec* is a trademark of Novartis AG

*Keytruda* is a trademark of Merck Sharp & Dohme Corp.

*Otezla* is a trademark of Amgen Inc.

*Plavix* is a trademark of Sanofi S.A.

*Yescarta* is a trademark of Kite Pharma, Inc.

*Tecentriq* is a trademark of Genentech, Inc.

Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of Bristol Myers Squibb and/or one of its subsidiaries.